- Report
- October 2024
- 183 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 250 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- December 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- May 2024
- 134 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Clinical Trials
- March 2025
- 450 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- May 2024
- 185 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- July 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- May 2024
- 130 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 130 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 130 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- June 2024
- 298 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- April 2024
- 200 Pages
Global
€4753EUR$5,000USD£3,993GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP

The Glioma Drug market is a subset of the larger Brain Cancer Drug market. Glioma is a type of brain cancer that is caused by the abnormal growth of glial cells in the brain. Treatment for glioma typically involves surgery, radiation therapy, chemotherapy, and targeted therapy. Drugs used to treat glioma include temozolomide, bevacizumab, and lomustine.
Glioma drugs are typically used in combination with other treatments, such as radiation and surgery, to improve patient outcomes. The market for glioma drugs is expected to grow due to the increasing prevalence of brain cancer and the development of new treatments.
Some companies in the Glioma Drug market include Novartis, Merck, Roche, and Pfizer. Show Less Read more